Saturday, October 31, 2026

Aspen Group Stock Plummets 12% In A Day

ViaNews Editorial Team

November 15, 2023

Aspen Group Stock Plummets 12% In A Day

(VIANEWS) - Aspen Group (NASDAQ: ASPU) shares experienced a dramatic 12.08% drop to EUR0.16 at 21:52 EST Tuesday after experiencing significant gains the prior session. Meanwhile, NASDAQ rose 2.06% to EUR14,051.12, reversing an earlier downward trend and positioning itself 67.19% below its 52-week high of EUR0.55.

About Aspen Group

Aspen Group is an education technology company based out of New York that offers online higher education in nursing, health sciences, business technology, arts & sciences & education via Aspen University and United States University. At last count (April 30th 2022) 13,334 students had enrolled for its various degree programs at Aspen Group's two institutions. Established in 1987 and located there today.

Yearly Analysis

According to available data, Aspen Group (ASPG) stock is currently trading at EUR0.16, significantly below its 52-week high of EUR0.55 but higher than its low point of EUR0.03 oversold levels. This suggests that investors may be anticipating a rebound of sorts. Noteworthy is Aspen Group's negative sales growth projection for both this and next year, which may signal challenges with revenue generation and would warn potential investors if there are no strong financial assets to rely on as a safety net. Before investing, investors must also carefully consider other factors, including earnings, profitability and competitive position in the market. It may be worthwhile conducting further research on Aspen Group before purchasing its stock.

Technical Analysis

Aspen Group's stock has experienced a recent downward trend in price, trading at less than its 50-day and 200-day moving averages of EUR0.15. According to the stochastic oscillator, however, the stock is considered oversold; suggesting it could soon experience a rebound. Investors should keep an eye on these indicators while taking the overall market conditions into consideration before making investment decisions.

Quarter Analysis

According to Aspen Group's sales growth numbers, its sales growth for both the current quarter and next is negative; this indicates a decline in sales that should raise alarm among investors who may believe their company is struggling to generate revenues. Year-on-year quarterly revenue growth has also decreased by 22.5% compared to last year - this indicates that revenue may have declined relative to its same period the prior year and is an alarming sign for investors, signalling that revenue may be trending down. However, investors should keep in mind that the data does not offer any explanation for why sales and revenue declined; to make informed investment decisions. Therefore, investors must conduct further investigation of factors contributing to such decline.

Equity Analysis

As per Aspen Group's financial information, its trailing twelve month earnings per share (EPS) stands at EUR-0.38, suggesting it is currently incurring losses and may not be appealing to investors. Further, the company's Return on Equity (ROE) for the twelve trailing months stands at negative -24.26% - this indicates that profits are not being generated efficiently and effectively which could cause concern among potential investors. Overall, Aspen Group's financial data indicates that they do not generate profits and have an unfavorable ROE rate which may put off potential investors. Therefore it would be prudent for potential investors to carefully consider this information and conduct additional research before making their investment decisions.

More news about Aspen Group (ASPU).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com